CareersInvestor RelationsPress RoomCOVID-19
  1. Home
  2. Laboratory Diagnostic Solutions India
  3. Plasma Proteins
  4. Plasma Protein Systems
  5. Next-generation BN II System

Next-generation BN II SystemThe nephelometric performance you trust.
The speed and workflow you need.

The next-generation BN II System combines the modern features that high-volume labs need – including onboard reagent cooling, the broadest menu of plasma protein assays,* and automation connectivity options – with proven nephelometric technology for confidence in results.

BN II System for automated plasma protein testing.

Benefits

Diagram illustrating nephelometric testing by measuring light scattered by particles in a sample.

Highly precise and reproducible, nephelometric technology provides additional sensitivity that is critical for testing diseases such as multiple myeloma, for which accurate free light chain test results are required to derive a true free light chain kappa-to-lambda ratio. With proven nephelometric technology, the next-generation BN II System provides:

  • Sophisticated antigen-excess pre-reaction protocols for more-accurate results and fewer repeats
  • Wide initial measuring ranges, reducing the need for retesting
  • Automatic specimen and reagent level detection prior to processing to ensure accuracy of results
  • Automatic serial dilution technology supports reliable results and helps to keep the dilution factor low
BN II System onboard reagent area for automated plasma protein testing.

With onboard reagent cooling, the next-generation BN II System:

  • Enhances reagent stability through integrated onboard cooling
  • Reduces manual reagent handling and daily reagent management activities
  • Helps improve workflow efficiency and maximize walkaway time
Graphic highlighting the broad assay menu available on the BN II System.

With the industry’s broadest plasma protein assay menu* of more than 70 plasma protein assays and applications across multiple sample types, the next-generation platform:

  • Consolidates testing on a single system with assay applications for serum, plasma, urine, and CSF samples
  • Helps reduce send-outs through a comprehensive test menu that supports assessment across a wide range of clinical conditions
BN II System automated pipetting at the dedicated dilution station.

Automation of serial dilutions in a dedicated station supports reliable quantification of both low- and high-concentration samples. The next-generation system’s advanced protocols:

  • Reduce the need for repeat testing, helping save time and reagents while also increasing confidence in results
  • Support accurate quantification across wide concentration ranges
  • Help maintain assay linearity across a broad measuring range
Sample tubes and reaction vessels loaded on the BN II System for high-volume testing

Designed to support labs with high testing volumes, the next-generation BN II System:

  • Supports up to 143 tests per hour in high-volume or free light chain testing environments†
  • Enables continuous loading of samples and consumables for uninterrupted operation and reduced downtime
Laboratory professional using the BN II System user interface for plasma protein testing

With password-protected access and an intuitive, secure user interface, the next-generation BN II System:

  • Helps control system access, permissions, and user responsibilities through a multi-dialog interface
  • Supports compliance protocols with applicable data privacy regulations, helping protect both personnel and patient information throughout the testing workflow
  • Provides detailed audit trails – including user actions, system events, and workflow activities – supporting compliance initiatives, including FDA 21 CFR Part 11 workflows
Comparison of BN II System N Latex FLC assays and OPTILITE FREELITE assays showing higher sensitivity at low concentrations

As part of an integrated laboratory workflow, the next-generation BN II System offers:

  • Efficient data exchange and streamlined result reporting through bidirectional communication
  • Data management integration within modern laboratory environments
  • Sample, process, and clinical insight efficiencies with connectivity to Atellica Diagnostics IT‡ and Protis Decision Support Software‡,§
Laboratory professional accessing the BN II System for flexible plasma protein testing automation

For labs looking to further reduce manual workflows, extend walkaway time, and streamline sample routing, the next-generation BN II System offers an automation-ready protein testing solution. Whether you are looking to realize the benefits of track-based automation now or want to leave your options open for the future, connecting to Aptio, FlexLab™, or FlexLab™ X Total Lab Automation can help your lab:

  • Reduce manual interaction
  • Extend walkaway time
  • Maintain continuous access to reagents and consumables
  • Improve biohazard safety
Diagram illustrating nephelometric testing by measuring light scattered by particles in a sample.

Highly precise and reproducible, nephelometric technology provides additional sensitivity that is critical for testing diseases such as multiple myeloma, for which accurate free light chain test results are required to derive a true free light chain kappa-to-lambda ratio. With proven nephelometric technology, the next-generation BN II System provides:

  • Sophisticated antigen-excess pre-reaction protocols for more-accurate results and fewer repeats
  • Wide initial measuring ranges, reducing the need for retesting
  • Automatic specimen and reagent level detection prior to processing to ensure accuracy of results
  • Automatic serial dilution technology supports reliable results and helps to keep the dilution factor low

Assays

Maximize your testing with the industry’s broadest plasma protein assay menu*

With the industry’s broadest plasma protein assay menu of more than 70 plasma protein assays and applications across multiple sample types, the next-generation BN II System enables labs to consolidate testing and reduce send-outs.

Download Brochure (pdf)
Quick search for supported assays

Plasma Protein Assays

Polyclonal and Monoclonal Gammopathies/Immune System

10
ß2-Microglobulin
FLC kappa
FLC lambda
Ig/Light Chain, type kappa
Ig/Light Chain, type lambda
IgA
IgD**,§
IgG
IgG subclasses 1-4
IgM

Kidney Disease

12
α1-Microglobulin urine
α2-Macroglobulin urine**
ß2-Microglobulin urine
ß-trace protein††
Albumin urine
Cystatin C
FLC kappa urine§
FLC lambda urine§
Ig/Light Chain, type kappa urine§
Ig/Light Chain, type lambda urine§
IgG urine
Transferrin urine

Inflammation

4
α1-Acid Glycoprotein (AAG)
hsCRP
Fibrinogen
SAA††

Autoimmune/Rheumatoid Diseases

8
ADNase B
ASL
Calprotectin**,††
C3c
C4
hsCRP
RF
TNFa Inhibitors (adalimumab, infliximab, etanercept)††

Cardiovascular Risk/Acute Cardiac Care

9
Albumin urine
Apo A-I
Apo B
Cystatin C
Fibrinogen
hsCRP
Homocysteine
Lp(a)
Myoglobin

Chronic Alcohol Abuse

2
CDT (Carbohydrate-deficient Transferrin)
Transferrin (for %CDT calculation)

Allergic Diseases

1
IgE

Nutritional Assessment

5
Albumin
CRP
Ferritin
Prealbumin
RBP (Retinol-binding Protein)

Coagulation Disorders

3
AT-III
Fibrinogen
Plasminogen

Anemia/Iron Metabolism

5
Ferritin
Haptoglobin
Hemopexin
sTfR (Soluble Transferrin Receptor)
Transferrin

Complement Activity

6
C1 Esterase Inhibitor
C1q**,††
C3c
C3 Proactivator**,††
C4
C5**,††

Blood-CSF Barrier Dysfunction

11
Albumin
Albumin CSF
ß-trace Protein (CSF leakage)§
FLC kappa CSF††
FLC lambda CSF††
IgA
IgA CSF
IgG
IgG CSF
IgM
IgM CSF

Other Specialty Analytes

6
α1-Antitrypsin
α2-Macroglobulin serum
Apo A-II††
Apo E††
Ceruloplasmin
Fibronectin††

Technical Details

Technical Specifications

Measuring principle

Nephelometry; measurement of the scattered light intensity at a fixed angle of 13-24°

Methods

More than 70 programmed assay protocols

Sample throughput

Effective: approximately 143 tests/hour, depending on the assay mix
Nominal: 225 tests/hour

Analysis method

Fixed-time kinetics, end-point measurement, VLin integral

Calibration

Multi-point calibration

Rack transport unit

Racks for up to 8 standard or control vials
Racks for up to 7 reagent vials
Racks for up to 10 sample tubes

Reagent handling

Up to 35 cooled onboard positions for reagents and supplemental reagents

Reagent cooling

Integrated onboard cooling at 14°C ± 1.5°C

Size of sample tubes

Diameter: 12-16 mm
Height: 55-100 mm
Supports pediatric microtubes up to 1.5 mL

Barcode types

Automatic barcode reading including 2/5 interleaved, Codabar, Code 39, Code 93 and Code 128

Sample dilution

Automatic dilution up to 1:160,000

Level detection

For samples, standards, controls, reagents and system liquid containers

Reaction cuvettes

60 reusable cuvettes

Sample types

Serum, plasma, urine, and CSF

Traceability

Complete traceability including operator information, test date/time, reagent details, controls, calibrations and kinetics

Instrument dimensions and weight

Analyzer dimensions (W × H × D): 124 × 92 × 63 cm (49 × 36 × 25 in.)
Analyzer weight: 150 kg (331 lb)

Computer and printer

Computer and monitor dimensions (W × H × D): approximately 43 × 43 × 17 cm (17 × 17 × 7 in.)

Printer dimensions (W × H × D): approximately 41 × 27 × 37 cm (16 × 11 × 15 in.)

Automation connectivity

Aptio Automation
FlexLab™ Automation
FlexLab™ X Total Lab Automation

Evidence

Nephelometric technology for quantification of high-sensitivity plasma protein assays

Highly precise and reproducible, nephelometric technology provides additional sensitivity that is critical for testing diseases such as multiple myeloma, for which accurate free light chain test results are required to derive a true free light chain kappa-to-lambda ratio.

1/3
Recommended by IMWG Guidelines01
Recommended by ESMO Guidelines01
Up to 68% more sensitive01
Graphic showing 2017 and an ESMO guidelines document icon.

Recommended by IMWG Guidelines

In 2014, the International Myeloma Working Group (IMWG) updated its diagnostic criteria for multiple myeloma. It established that a serum-free light chain (FLC) assay measured via nephelometry or turbidimetry can define active multiple myeloma even before traditional CRAB organ damage appears, provided specific quantitative thresholds are met.1

Graphic showing 2017 and an ESMO guidelines document icon.
Graphic showing 2017 and an ESMO guidelines document icon.
Comparison of BN II System N Latex FLC assays and OPTILITE FREELITE assays showing higher sensitivity at low concentrations.
1/3
*
As of August 2026. Data on file.
†
Based on internal throughput studies comparing several different assay mix panels on the legacy BN II System and next-generation BN II System. Throughput improvement is dependent on assay mix.
‡
Sold separately.
§
Not available for sale in the U.S.
Based on the limits of quantification reported in the manufacturers’ IFUs.
**
Alliance application manufactured by third party, distributed by Siemens Healthcare Diagnostics Inc.
††
Research use only in the U.S.
1
Rajkumar et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15:e538-48.
2
Moreau et al. Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28(Suppl 4):iv52-61.
3
Siemens Healthineers N Latex FLC kappa/N Latex FLC lambda IFU, 11541959_en Rev. 12 (Outside USA).
4
The Binding Site Optilite Freelite Kappa Free Kit IFU, INS016.OPT.
5
The Binding Site Optilite Freelite Lambda Free Kit IFU, INS018.OPT.
Aptio Automation is manufactured by Inpeco and is exclusively distributed by Siemens Healthcare Diagnostics Inc. FlexLab™ and FlexLab™ X are manufactured by Inpeco and distributed by Siemens Healthcare Diagnostics Inc. FlexLab is a trademark of Inpeco SA.
The products/features (mentioned herein) are not commercially available in all countries. Due to regulatory reasons, their future availability cannot be guaranteed. Please contact your local Siemens Healthineers organization for further details.
Contact